Chordia Therapeutics Inc

Chordia Therapeutics Inc is a Japan-based clinical-stage biotech company established in 2017. The company's slogan "We are passionate to deliver first in class cancer drugs to patients from Japan" highlights its dedication to addressing the unmet medical needs in cancer treatment. Specializing in the development of novel therapies, Chordia Therapeutics aims to revolutionize cancer treatment. Notably, the company was spun out from Takeda Pharmaceutical in November 2017, showcasing its roots in a renowned pharmaceutical entity. In terms of investments, Chordia Therapeutics secured a significant ¥3.00B Series B investment on 01 April 2019. The investors in this round included Mitsubishi UFJ Capital, JAFCO Japan, Nippon Venture Capital, SMBC Venture Capital, Shinsei Capital Partners, and Kyoto University Innovation Capital. This diverse set of investors demonstrates the confidence and support from various sectors including finance, academia, and industry. The company's key focus on addressing the high unmet needs in cancer treatment, combined with its strong financial backing from reputable investors, positions Chordia Therapeutics as a promising entity in the biotech industry. With a solid foundation and a clear mission, the company is poised to make significant strides in the development of groundbreaking cancer therapies.